Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy

PLoS One. 2017 Jul 6;12(7):e0180513. doi: 10.1371/journal.pone.0180513. eCollection 2017.

Abstract

Background: Recent studies have reported prognosis differences between male and female heart failure patients following cardiac resynchronization therapy (CRT). However, the potential clinical factors that underpin these differences remain to be elucidated.

Methods: A meta-analysis was performed to investigate the factors that characterize sex-specific differences following CRT. This analysis involved searching the Medline (Pubmed source) and Embase databases in the period from January 1980 to September 2016.

Results: Fifty-eight studies involving 33445 patients (23.08% of whom were women) were analyzed as part of this study. Only patients receiving CRT with follow-up greater than six months were included in our analysis. Compared with males, females exhibited a reduction of 33% (hazard ratio, 0.67; 95% confidence interval, 0.62-0.73; P < 0.0001) and 42% (hazard ratio, 0.58; 95% confidence interval, 0.46-0.74; P = 0.003) in all-cause mortality and heart failure hospitalization or heart failure, respectively. Following a stratified analysis of all-cause mortality, we observed that ischemic causes (p = 0.03) were likely to account for most of the sex-specific differences in relation to CRT.

Conclusion: These data suggest that women have a reduced risk of all-cause mortality and heart failure hospitalization or heart failure following CRT. Based on the results from the stratified analysis, we observed more optimal outcomes for females with ischemic heart disease. Thus, ischemia are likely to play a role in sex-related differences associated with CRT in heart failure patients. Further studies are required to determine other indications and the potential mechanisms that might be associated with sex-specific CRT outcomes.

MeSH terms

  • Cardiac Resynchronization Therapy / methods*
  • Female
  • Heart Failure / mortality*
  • Heart Failure / therapy
  • Humans
  • Male
  • Myocardial Ischemia / mortality*
  • Myocardial Ischemia / therapy
  • Sex Factors*

Grants and funding

This work was supported by National Natural Science Foundation of China (No. 81600267) to Zhonglin Han. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.